Interleukin 2 subcutaneous injection

DRUG3 trials

Sponsors

Second Affiliated Hospital of Soochow University, Hangzhou Huasai Biomedicine Co., Ltd.

Conditions

Advanced NSCLCAdvanced Solid TumorClear Cell Renal Cell CarcinomaRefractory Tumor

Phase 1

Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer(FASTIL-Renal01)

RecruitingNCT07770802

Hangzhou Huasai Biomedicine Co., Ltd.Clear Cell Renal Cell Carcinoma

Start: 2026-08-23End: 2028-08-01Target: 15Updated: 2026-10-14

A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02)

RecruitingNCT07830342

Hangzhou Huasai Biomedicine Co., Ltd.Advanced NSCLC

Start: 2026-09-21End: 2028-10-01Target: 24Updated: 2026-10-14

Phase 2

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Second Affiliated Hospital of Soochow UniversityAdvanced Solid Tumor, Refractory Tumor

Start: 2023-06-16End: 2024-12-31Target: 30Updated: 2023-09-21

Related Papers

Efficacy and Safety of PRaG Therapy in Elderly Patients with Advanced Malignant Tumors: A Prospective, Multicenter Clinical Study Protocol (PRaG 9.0 Study)

Technology in Cancer Research & Treatment2025-06-01